High expression levels of bonemorphogenetic protein-2 and p-

glycoprotein related withprogressivity in patient with

osteosarcomaby I Ketut Suyasa

Submission date: 05-Sep-2018 09:16AM (UTC+0700)Submission ID: 996991118File name: tein_related_with_progressivity_in_patient_with_osteosarcoma.pdf (445.51K)Word count: 3218Character count: 17742

18%SIMILARITY INDEX

10%INTERNET SOURCES

14%PUBLICATIONS

6%STUDENT PAPERS

1 2%

2 2%

3 1%

4 1%

5 1%

6 1%

7 1%

High expression levels of bone morphogenetic protein-2 andp-glycoprotein related with progressivity in patient withosteosarcomaORIGINALITY REPORT

PRIMARY SOURCES

Submitted to Central Queensland UniversityStudent Paper

mdanderson.influuent.utsystem.eduInternet Source

Submitted to Clovis Community CollegeStudent Paper

mobile.repository.ubn.ru.nlInternet Source

Dsouza, Priya, and Maria Kuruville."Dyslipidemia in psoriasis: as a risk forcardiovascular disease", International Journalof Research in Medical Sciences, 2013.Publicat ion

www.ijbcp.comInternet Source

Ho, G-T. Moodie, F.M. Satsangi, J.. "Multidrugresistance 1 gene (P-glycoprotein 170): an

8 1%

9 1%

10 1%

11 1%

12 <1%

important determinant in gastrointestinaldisea", Gut, May 2003 IssuePublicat ion

Submitted to University of DerbyStudent Paper

Fujiwara, Tomohiro, Ryou-u Takahashi,Nobuyoshi Kosaka, Yutaka Nezu, Akira Kawai,Toshifumi Ozaki, and Takahiro Ochiya. "RPN2Gene Confers Osteosarcoma Cell MalignantPhenotypes and Determines ClinicalPrognosis", Molecular Therapy — NucleicAcids, 2014.Publicat ion

Liu, Xudong, Bingfang Zeng, Jie Ma, andChunling Wan. "Comparative ProteomicAnalysis of Osteosarcoma Cell and HumanPrimary Cultured Osteoblastic Cell", CancerInvestigation, 2009.Publicat ion

He, Hongtao, Jiangdong Ni, and Jun Huang."Molecular mechanisms of chemoresistance inosteosarcoma (Review)", Oncology Letters,2014.Publicat ion

mext-cancerinfo.tri-kobe.orgInternet Source

circres.ahajournals.org

13 <1%

14 <1%

15 <1%

16 <1%

17 <1%

18 <1%

19 <1%

Internet Source

www.thieme-connect.comInternet Source

Shen, F., B. J. Bailey, S. Chu, A. K. Bence, X.Xue, P. Erickson, A. R. Safa, W. T. Beck, and L.C. Erickson. "Dynamic Assessment ofMitoxantrone Resistance and Modulation ofMultidrug Resistance by Valspodar (PSC833) inMultidrug Resistance Human Cancer Cells",Journal of Pharmacology and ExperimentalTherapeutics, 2009.Publicat ion

Submitted to Seminole Community CollegeStudent Paper

hrcak.srce.hrInternet Source

Tang Liu, Zhihong Li, Qing Zhang, Karen DeAmorim Bernstein et al. "Targeting ABCB1(MDR1) in multi-drug resistant osteosarcomacells using the CRISPR-Cas9 system to reversedrug resistance", Oncotarget, 2016Publicat ion

Anja Luetke, Paul A. Meyers, Ian Lewis,Heribert Juergens. "Osteosarcoma treatment –Where do we stand? A state of the art review",

20 <1%

21 <1%

22 <1%

23 <1%

24 <1%

25 <1%

Cancer Treatment Reviews, 2014Publicat ion

www.everettclinic.comInternet Source

www.omicsonline.orgInternet Source

Haijun Tian, Jie Zhao, Elsa J. Brochmann,Jeffrey C. Wang, Samuel S. Murray. "Bonemorphogenetic protein-2 and tumor growth:Diverse effects and possibilities for therapy",Cytokine & Growth Factor Reviews, 2017Publicat ion

Stefano Ferrari. "Evaluation of P-glycoprotein,HER-2/ErbB-2, p53, and Bcl-2 in primary tumorand metachronous lung metastases in patientswith high-grade osteosarcoma", Cancer,05/01/2004Publicat ion

www.healio.comInternet Source

Li-Tzu Lee, Yong-Kie Wong, Man-Yee Chan,Kuo-Wei Chang, Shyh-Chang Chen, Chiou-TuzChang, John Wang. "The correlation betweenHIF-1 alpha and VEGF in oral squamous cellcarcinomas: Expression patterns andquantitative immunohistochemical analysis",

26 <1%

27 <1%

28 <1%

29 <1%

30 <1%

31 <1%

Journal of the Chinese Medical Association,2018Publicat ion

www.jsnm.orgInternet Source

Submitted to Pellissippi State TechnicalCommunity CollegeStudent Paper

Hattinger, Claudia Maria, Francesca Michelacci,Federica Sella, Giovanna Magagnoli, StefaniaBenini, Marco Gambarotti, EmanuelaPalmerini, Piero Picci, Massimo Serra, andStefano Ferrari. "ercc1 protein expressionpredicts survival in patients with high-grade,non-metastatic osteosarcoma treated withneoadjuvant chemotherapy", Histopathology,2015.Publicat ion

Cañadell s Pediatric Bone Sarcomas, 2016.Publicat ion

Jenny E Felin. "Nuclear variants of bonemorphogenetic proteins", BMC Cell Biology,2010Publicat ion

Gaetano Bacci. "Predictive factors for localrecurrence in osteosarcoma 540 patients withextremity tumors followed for minimum 2.5

32 <1%

Exclude quotes On

Exclude bibliography On

Exclude matches < 2 words

years after neoadjuvant chemotherapy", ActaOrthopaedica, 6/1/1998Publicat ion

Carragee, Eugene J.. "Cancer Risk After Use ofRecombinant Bone Morphogenetic Protein-2for Spinal Arthrodesis", The Journal of Boneand Joint Surgery (American), 2013.Publicat ion

FINAL GRADE

/0

High expression levels of bone morphogenetic protein-2 andp-glycoprotein related with progressivity in patient withosteosarcomaGRADEMARK REPORT

GENERAL COMMENTS

Instructor

PAGE 1

PAGE 2

PAGE 3

PAGE 4

PAGE 5